PL3290052T3 - Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów - Google Patents

Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów

Info

Publication number
PL3290052T3
PL3290052T3 PL17191118T PL17191118T PL3290052T3 PL 3290052 T3 PL3290052 T3 PL 3290052T3 PL 17191118 T PL17191118 T PL 17191118T PL 17191118 T PL17191118 T PL 17191118T PL 3290052 T3 PL3290052 T3 PL 3290052T3
Authority
PL
Poland
Prior art keywords
growth factor
monoclonal antibodies
factor receptor
fibroblast growth
antibodies specific
Prior art date
Application number
PL17191118T
Other languages
English (en)
Inventor
Kim KYUNG JIN
Wei-Meng Zhao
Hangil Park
Original Assignee
Galaxy Biotech, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galaxy Biotech, Llc filed Critical Galaxy Biotech, Llc
Publication of PL3290052T3 publication Critical patent/PL3290052T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL17191118T 2008-11-07 2009-11-06 Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów PL3290052T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11268608P 2008-11-07 2008-11-07
US16487009P 2009-03-30 2009-03-30
PCT/US2009/063647 WO2010054265A2 (en) 2008-11-07 2009-11-06 Monoclonal antibodies to fibroblast growth factor receptor 2
EP17191118.3A EP3290052B1 (en) 2008-11-07 2009-11-06 Monoclonal antibodies to fibroblast growth factor receptor 2
EP14188785.1A EP2842573B1 (en) 2008-11-07 2009-11-06 Monoclonal antibodies to Fibroblast Growth Factor receptor 2
EP09825523.5A EP2365828B1 (en) 2008-11-07 2009-11-06 Monoclonal antibodies to fibroblast growth factor receptor 2

Publications (1)

Publication Number Publication Date
PL3290052T3 true PL3290052T3 (pl) 2020-06-29

Family

ID=42153600

Family Applications (3)

Application Number Title Priority Date Filing Date
PL17191118T PL3290052T3 (pl) 2008-11-07 2009-11-06 Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów
PL09825523T PL2365828T3 (pl) 2008-11-07 2009-11-06 Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów
PL14188785T PL2842573T3 (pl) 2008-11-07 2009-11-06 Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL09825523T PL2365828T3 (pl) 2008-11-07 2009-11-06 Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów
PL14188785T PL2842573T3 (pl) 2008-11-07 2009-11-06 Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów

Country Status (20)

Country Link
US (8) US8101723B2 (pl)
EP (4) EP2365828B1 (pl)
JP (8) JP5627591B2 (pl)
KR (1) KR101699432B1 (pl)
CN (1) CN102131524B (pl)
AU (1) AU2009313357B2 (pl)
BR (1) BRPI0917315B8 (pl)
CA (3) CA2733668C (pl)
DK (3) DK2842573T3 (pl)
ES (3) ES2523740T3 (pl)
HR (2) HRP20171640T1 (pl)
HU (1) HUE035700T2 (pl)
LT (2) LT2842573T (pl)
MX (1) MX2011000455A (pl)
NO (1) NO2842573T3 (pl)
PL (3) PL3290052T3 (pl)
PT (3) PT3290052T (pl)
RU (1) RU2546254C9 (pl)
SI (2) SI2842573T1 (pl)
WO (1) WO2010054265A2 (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
US20110059091A1 (en) * 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
PL3290052T3 (pl) 2008-11-07 2020-06-29 Galaxy Biotech, Llc Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów
US8481688B2 (en) * 2010-05-11 2013-07-09 Aveo Pharmaceuticals, Inc. Anti-FGFR2 antibodies
CN103201287B (zh) * 2010-08-12 2016-04-13 艾托生物有限公司 成纤维细胞生长因子受体2的致癌异构体的抗体分子及其用途
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
AR088941A1 (es) * 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
MX2014007121A (es) * 2011-12-14 2014-09-04 Seattle Genetics Inc Nuevos conjugados de principio activo-ligante (adc) y su uso.
EP2822968B1 (en) 2012-03-08 2018-01-10 Janssen Vaccines & Prevention B.V. Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
CN104334724B (zh) 2012-04-09 2020-09-01 第一三共株式会社 抗-fgfr2抗体
WO2014089193A1 (en) * 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
JP6488236B2 (ja) * 2012-12-21 2019-03-20 ヤンセン バイオテツク，インコーポレーテツド 可溶型線維芽細胞増殖因子受容体の高感度多重イムノアッセイ
CN103145843B (zh) * 2013-02-20 2014-10-29 暨南大学 抗成纤维细胞生长因子受体的单链抗体
KR20150123250A (ko) 2013-03-06 2015-11-03 제넨테크, 인크. 암 약물 내성의 치료 및 예방 방법
CN105452296B (zh) * 2013-08-01 2020-09-25 戊瑞治疗有限公司 无岩藻糖基化抗fgfr2iiib抗体
US9931401B2 (en) * 2013-10-08 2018-04-03 Daiichi Sankyo Company, Limited Combination comprising anti-fibroblast growth factor receptor 2 (FGFR2) antibody and a tyrosine kinase inhibitor
CN103757026B (zh) * 2013-12-20 2017-04-05 广州圣露生物技术有限公司 FGFR2b胞外段的基因序列、多肽及其应用
EP3154589A1 (en) 2014-06-13 2017-04-19 Genentech, Inc. Methods of treating and preventing cancer drug resistance
CN104231079A (zh) * 2014-09-12 2014-12-24 暨南大学 一种靶向bFGF高亲和力受体结合位点的抗体及其应用
TW201642904A (zh) * 2015-04-08 2016-12-16 第一三共股份有限公司 含抗ｆｇｆｒ２抗體及其他藥劑之組成物
US10881734B2 (en) 2015-04-20 2021-01-05 Daiichi Sankyo Company, Limited Monoclonal antibodies to human fibroblast growth factor receptor 2 (HFGFR2) and methods of use thereof
RU2638457C2 (ru) * 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
RU2745707C2 (ru) 2015-11-23 2021-03-30 Файв Прайм Терапьютикс, Инк. Ингибиторы fgfr2 отдельно или в комбинации с иммуностимулирующими агентами в лечении рака
JP7034489B2 (ja) 2016-03-15 2022-03-14 アイタブメッド （エイチケイ） リミテッド 多重特異性Ｆａｂ融合タンパクおよびその使用
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
LT3624837T (lt) 2017-05-16 2025-10-10 Anti-fgfr2 antikūnai derinyje su chemoterapijos agentais vėžio gydymui
MX2019014504A (es) 2017-06-02 2020-07-20 Merck Patent Gmbh Inmunoglobulinas de union a agrecano.
US10882915B2 (en) 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
EP3700568A4 (en) 2017-10-24 2021-11-10 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
WO2019084067A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODIES AND METHODS OF USE
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
UA130250C2 (uk) 2018-10-05 2025-12-31 Файв Прайм Терапьютикс, Інк. Рідкий фармацевтичний склад та композиція на основі антитіла до fgfr2
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
WO2021129656A1 (en) * 2019-12-24 2021-07-01 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel anti-fgfr2b antibodies
CN114846029A (zh) * 2019-12-24 2022-08-02 迪哲(江苏)医药股份有限公司 新颖抗fgfr2b抗体
EP4161566A4 (en) * 2020-06-03 2024-06-12 The Broad Institute, Inc. ANTAGONISTIC BIPARATOPIC ANTIBODIES SPECIFICALLY BINDING FIBROBLAST GROWTH FACTOR RECEPTOR 2 AND METHODS OF USE THEREOF
CA3190569A1 (en) 2020-10-22 2022-04-28 Christopher Daly Anti-fgfr2 antibodies and methods of use thereof
CN116847876A (zh) * 2020-12-29 2023-10-03 深圳福沃药业有限公司 抗fgfr2抗体及其用途
WO2023056916A1 (zh) * 2021-10-08 2023-04-13 深圳福沃药业有限公司 Adcc增强型抗fgfr2抗体及其用途
TW202342527A (zh) 2022-02-25 2023-11-01 美商安進公司 鱗狀非小細胞肺癌之治療
WO2024067876A1 (en) * 2022-09-30 2024-04-04 3H Pharmaceuticals Co., Ltd. Anti-fgfr2b antibodies and uses thereof
CN118852431A (zh) * 2023-04-28 2024-10-29 武汉人福创新药物研发中心有限公司 抗FGFR2b单抗
EP4714976A1 (en) * 2023-05-19 2026-03-25 Sunshine Lake Pharma Co., Ltd. Anti-fgfr2 antibody and use thereof
CN119855835A (zh) * 2023-06-13 2025-04-18 南京维立志博生物科技股份有限公司 基于共同轻链产生双特异性抗体的方法
WO2025130905A1 (zh) * 2023-12-18 2025-06-26 山东先声生物制药有限公司 抗FGFR2b抗体-药物缀合物及其应用
WO2025218662A1 (zh) * 2024-04-16 2025-10-23 杭州中美华东制药有限公司 抗成纤维细胞生长因子受体2b的抗体及其用途
TW202547875A (zh) * 2024-05-09 2025-12-16 大陸商正大天晴藥業集團股份有限公司 靶向成纖維細胞生長因子受體2IIIb的抗體及其應用
WO2026007196A1 (zh) * 2024-07-02 2026-01-08 安博泰克药业有限公司 特异性结合FGFR2b的抗体及其与药物的缀合物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3039802B2 (ja) 1989-07-06 2000-05-08 ザ リージェンツ オブザ ユニバーシティ オブ カリフォルニア 繊維芽細胞成長因子のための受容体
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5863888A (en) 1990-07-06 1999-01-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Human Bek Fibroblast growth factor receptor
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
EP0723556A4 (en) * 1993-10-14 2003-03-19 Immunex Corp FAS ANTAGONISTS AND THEIR APPLICATIONS
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
AU3494397A (en) 1996-06-18 1998-01-07 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Fibroblast growth factor receptor activating gene i and related compositions and methods
US20030143676A1 (en) 1999-03-25 2003-07-31 Genesis Research And Development Corporation Limited Fibroblast growth factor receptors and methods for their use
IL145941A (en) * 1999-04-28 2007-08-19 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting vegf
JP2001302699A (ja) 2000-04-17 2001-10-31 Nichirei Corp ヒトｋｇｆｒに対する抗体
US20020115603A1 (en) 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease
WO2002100348A2 (en) * 2001-06-13 2002-12-19 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
JP2005530687A (ja) 2002-01-31 2005-10-13 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ Ｆｇｆｒアゴニスト
KR100493460B1 (ko) * 2002-08-29 2005-06-07 재단법인서울대학교산학협력재단 암 세포에서 발현되는 ｆｇｆｒ2 이성체
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
NZ544797A (en) 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
WO2005066211A2 (en) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
US7872016B2 (en) 2004-05-25 2011-01-18 Yale University Method for treating skeletal disorders resulting from FGFR malfunction
US7890267B2 (en) 2006-03-31 2011-02-15 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
EP2018442A2 (en) * 2006-05-12 2009-01-28 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
JP4560582B2 (ja) 2006-06-02 2010-10-13 アベオ ファーマシューティカルズ， インコーポレイテッド 肝細胞成長因子（ｈｇｆ）結合蛋白質
SG158112A1 (en) 2006-06-02 2010-01-29 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins
WO2007144893A2 (en) 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
HUE028379T2 (en) 2006-09-29 2016-12-28 Oncomed Pharm Inc Preparations and procedures for the diagnosis and treatment of cancer
US8394927B2 (en) * 2006-11-03 2013-03-12 U3 Pharma Gmbh FGFR4 antibodies
AU2008230880B2 (en) * 2007-03-23 2014-04-24 The Translational Genomics Research Institute Method of diagnosing, classifying and treating endometrial cancer and precancer
WO2009052830A1 (en) 2007-10-22 2009-04-30 Genmab A/S Novel antibody therapies
US20110059091A1 (en) 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
PL3290052T3 (pl) 2008-11-07 2020-06-29 Galaxy Biotech, Llc Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów
US20120301482A1 (en) 2009-08-25 2012-11-29 National Jewish Health Methods and compositions for treatment of lung injury

Also Published As

Publication number Publication date
PL2365828T3 (pl) 2015-04-30
JP2014240385A (ja) 2014-12-25
JP6445496B2 (ja) 2018-12-26
NO2842573T3 (pl) 2018-02-24
KR20110081141A (ko) 2011-07-13
JP2017019807A (ja) 2017-01-26
JP5627591B2 (ja) 2014-11-19
LT2842573T (lt) 2017-12-11
JP2020096615A (ja) 2020-06-25
US20100196364A1 (en) 2010-08-05
HRP20171640T1 (hr) 2018-01-12
US20230242650A1 (en) 2023-08-03
PL2842573T3 (pl) 2018-04-30
CA3166399A1 (en) 2010-05-14
RU2546254C2 (ru) 2015-04-10
BRPI0917315B1 (pt) 2020-12-08
JP6960485B2 (ja) 2021-11-05
HRP20200090T1 (hr) 2020-04-03
JP2022008996A (ja) 2022-01-14
HK1207974A1 (en) 2016-02-19
EP2365828A4 (en) 2012-06-06
US20200347141A1 (en) 2020-11-05
US9834609B2 (en) 2017-12-05
LT3290052T (lt) 2020-02-25
DK3290052T3 (da) 2020-02-03
ES2523740T3 (es) 2014-12-01
HK1249053A1 (en) 2018-10-26
US20140193899A1 (en) 2014-07-10
US10689448B2 (en) 2020-06-23
SI2842573T1 (en) 2018-01-31
PT3290052T (pt) 2020-02-06
DK2842573T3 (en) 2017-10-30
EP2365828B1 (en) 2014-10-15
US9382324B2 (en) 2016-07-05
ES2646168T3 (es) 2017-12-12
JP2023116746A (ja) 2023-08-22
ES2770134T3 (es) 2020-06-30
SI3290052T1 (sl) 2020-07-31
CN102131524B (zh) 2014-05-14
CA2733668C (en) 2022-08-30
JP2025032085A (ja) 2025-03-11
CA3166399C (en) 2026-02-03
CN102131524A (zh) 2011-07-20
US20120134994A1 (en) 2012-05-31
JP6661734B2 (ja) 2020-03-11
AU2009313357A1 (en) 2010-05-14
EP2365828A2 (en) 2011-09-21
AU2009313357B2 (en) 2015-06-11
US10138301B2 (en) 2018-11-27
EP3290052A1 (en) 2018-03-07
EP2842573B1 (en) 2017-09-27
US20180094063A1 (en) 2018-04-05
BRPI0917315A2 (pt) 2015-11-17
US8101723B2 (en) 2012-01-24
JP2012508184A (ja) 2012-04-05
WO2010054265A2 (en) 2010-05-14
DK2365828T3 (en) 2014-12-08
KR101699432B1 (ko) 2017-01-24
PT2365828E (pt) 2014-12-12
HK1160012A1 (en) 2012-08-10
PT2842573T (pt) 2017-12-04
RU2011141890A (ru) 2013-04-27
CA2733668A1 (en) 2010-05-14
MX2011000455A (es) 2011-02-25
RU2546254C9 (ru) 2015-07-10
JP2019052165A (ja) 2019-04-04
JP6342223B2 (ja) 2018-06-13
EP3290052B1 (en) 2019-12-25
US20190153105A1 (en) 2019-05-23
US20160362496A1 (en) 2016-12-15
CA3287843A1 (en) 2026-03-02
WO2010054265A3 (en) 2010-09-16
EP2842573A1 (en) 2015-03-04
HUE035700T2 (en) 2018-05-28
JP7301106B2 (ja) 2023-06-30
US8603987B2 (en) 2013-12-10
BRPI0917315B8 (pt) 2021-05-25
EP3783024A1 (en) 2021-02-24

Similar Documents

Publication Publication Date Title
PL2842573T3 (pl) Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów
LTPA2018017I1 (lt) Žmogaus CGRP receptorių rišantys antikūnai
DK2131860T3 (da) Anti-sclerostin-antistoffer
PT2195026E (pt) Anticorpos anti-esclerostina
BRPI0918768A2 (pt) composições de anticorpo recombinante de anti-receptor do fator de crescimento epidérmico.
EP2324359A4 (en) MONOCLONAL ANTIBODY STRO-4
EP2254911A4 (en) HUMANIZED ANTI-C5aR ANTIBODIES
EP2501800A4 (en) HUMAN MONOCLONAL ANTIBODIES AGAINST HUMAN NUCLEOLIN
EP2206775A4 (en) ANTI-IL-6 receptor antibody
BRPI0819165A2 (pt) Anticorpos anti-vegf
EP2331579A4 (en) MONOCLONAL ANTIBODIES
CR20170001A (es) Anticuerpos anti factor d humanizados
SMT201700083B (it) Anticorpi monoclonali
PL3059246T3 (pl) Zmodyfikowany region stały przeciwciała
BRPI0923359A2 (pt) Anticorpos anti-igf
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
BRPI0814111A2 (pt) Anticorpo monoclonal citotóxico anticâncer
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
EP2424891A4 (en) MONOCLONAL ERG ANTIBODIES
DK2094728T3 (da) Fremgangsmåder til anvendelse for human-adapterende monoklonale antistoffer
PL2365987T3 (pl) Przeciwciała anty-HER4 swoiste dla określonej izoformy
BRPI0814116A2 (pt) Anticorpo monoclonal citotóxico anticâncer
BRPI0813520A2 (pt) Anticorpo monoclonal citotóxico anticâncer
TWI348915B (en) Anti-vegf monoclonal antibody
TH0801006146A (th) แอนติ-vegf แอนติบอดี